# 1. Financial Performance ## A. Key Figures * Standalone Revenue: **₹1,000 Cr** (first time) (+8.1%) · Consolidated Revenue (+~10%) * EBITDA Margin: 35.9% (+520 bps YoY) · EBITDA Growth: 26.7% * **PAT Margin:** **3%** (+290 bps YoY) · **EPS Growth:** **9%** * **Cash Balance:** **₹2,426 Cr** ## B. Revenue Growth * **Milestone Quarter:** Standalone revenue surpassed ₹1,000 Cr for the first time despite two-quarter supply disruption from CMO facility incident. * **GenMed Recovery Underway:** Core business, contributing **over 75% of revenue**, temporarily slowed to low single-digit growth but is now rebounding post-supply normalization. ## C. Profit Margins * **Sharp Margin Expansion:** EBITDA margin up 520 bps YoY on gross margin gains and cost discipline, even after absorbing a **₹8 Cr one-off labor cost**. * **Sustained Profitability Uplift:** EBITDA margin has tripled from 3% two years ago, reflecting structural improvements from portfolio transformation and operational efficiency. * **Margin Profile Stability:** Base business supports overall stability with **higher margins than injectables**, offsetting dilution from injectable launch costs. ## D. Cash Flow & Balance Sheet * **Healthy Liquidity:** Strong cash balance of ₹2,426 Cr supports financial flexibility and resilience. * **Employee Cost Dynamics:** Q-on-Q dip of ~10% in employee expenses due to **₹16 Cr one-time benefit** and prior-year provision reversals; future growth expected at **7–8% inflationary pace**. * **Labour Code Impact Isolated:** ₹12 Cr cost from new Labour Code treated as **exceptional item**, preserving clarity on underlying cost trends. --- # 2. Product & Therapy Performance ## A. Key Figures * **Therapy Area Growth:** 10% in represented areas (+slight market outperformance) * **Vaccine Growth:** 11% in the quarter (6 consecutive quarters of double-digit growth) * **Shingrix Revenue:** ₹75 Cr CY25 (calendar year basis) * **Shingrix Doses:** ~100,000 doses (previous calendar year) ## B. Anti-infectives & Vitamins * **Recovery in Core Therapies:** Anti-infectives rebounded after prior weakness, supported by resolved supply constraints and strong demand in vitamins, pain management, and vaccines. * **Market Outperformance:** GenMeds portfolio showed evolution index above 100, with **Augmentin, Ceftum, and T-Bact** delivering double-digit growth. * **Stable Growth Foundation:** Base business (GenMeds + established vaccines) expected to grow at **high single-digit CAGR** over next five years. ## C. Vaccines & Shingrix * **Sustained Vaccine Momentum:** Pediatric and adult vaccines both strengthened, with **Boostrix, Varilrix, and Havrix** driving double-digit growth and share gains. * **Shingrix Scaling Successfully:** Now a key growth driver, with **monthly patient reach of 9,000–10,000** and expanding HCP/HCO engagement via CVMD-linked strategy. * **Strategic Shift Paying Off:** Shingrix growth anchored in bi-directional link between shingles prevention and cardiovascular metabolic disease, enhancing clinical relevance. ## D. Oncology & Specialty * **Specialty Launches Gaining Traction:** **Trelegy Ellipta** and **Nucala** driving growth, with Nucala adding **~100 new patients monthly** in Q3. * **Major Expansion in Jemperli’s Addressable Market:** Eligible patient pool for endometrial cancer increased **from ~800 to ~6,000** with first-line approval, unlocking significant future potential. * **Oncology as Strategic Growth Vector:** Recent launches of **Zejula and Jemperli** mark entry into oncology, a core focus for next 3–5 years despite early-stage ramp. --- # 3. Launch & Pipeline Progress ## A. Key Figures * **Freshness Index Target:** **10%** (2–3 years) · **10–15%** expected contribution next fiscal [#] · **20–25%** projected over 5–7 years * **Eligible Patient Pool:** **~800** for initial Jemperli indication ## B. New Product Contribution * **Oncology Launch Momentum:** First full-quarter availability of Zejula and Jemperli achieved, with Jemperli’s label expanded to first-line endometrial cancer, significantly broadening its reach. * **Pipeline-Driven Growth Strategy:** Belantamab (Blenrep) for multiple myeloma set for launch in FY25 (Q2/Q3), anchoring a new Hematology business focused on blood cancers. * **Sustained Innovation Trajectory:** New products including Shingrix, RSV vaccine, and oncology assets expected to drive **10–15% of topline** next year, with long-term target of **20–25%** from recent launches. * **Commercial Model Evolution:** Specialty launches to use direct supply to high-impact facilities over traditional chains, ensuring speed-to-market in critical care settings. * **Core Business Resilience:** Established GenMeds and vaccines franchise (valued at **over INR 3,500 Cr**) remains foundational, not to be displaced by new launches. ## C. Clinical Trial Readouts * **Differentiated Clinical Profile:** Dostarlimab (Jemperli) demonstrates **overall survival benefit** in intent-to-treat population — a rare documented outcome driving strong stakeholder confidence. * **Global Trial Integration:** India played key role in pivotal trials for Bepirovirsen (Hepatitis B functional cure) and RSV vaccine, enabling early access and reinforcing local evidence generation. * **Innovation Expansion via Acquisitions:** Parent company’s global acquisitions targeting high-impact areas like food allergies, enhancing future pipeline depth. * **Next-Gen Pipeline Build:** GSK advancing ADCs (e.g., B3H7) with plans for **12–15 India indications over five years**, signaling long-term biopharma commitment. ## D. Global-to-Local Launches * **Strategic Shift to Innovation:** GSK leveraging established base to reduce launch lag and accelerate biopharma innovation in India, aligning with national shift toward specialty care. * **Local Launch Vehicle Confirmed:** New assets like Zejula and Jemperli launched via GSK Pharma India, affirming the listed entity as primary route for future specialty introductions. * **Agile Supply Chain for Specialty Care:** Focus on rapid delivery to hospitals and day care centers, particularly in oncology, supported by in-house (Nashik) and CMO network. --- # 4. Volume & Pricing Trends ## A. Key Figures * **Market Growth:** **~9%** external market growth in Q3 FY2026 · **6%** acute market growth * **NLEM Product Value:** **>₹200 Cr** annual value for Ceftum and T-Bact post-price cut * **Volume Trend:** **3–4% CAGR** volume growth over four years for Ceftum and T-Bact ## B. Market Growth Recovery * **Recovery Underway:** External market rebounded in Q3 with strong momentum, driven by positive volume trends, pricing, and new product launches after prior softness. * **Supply Normalization:** CMO fire-related disruptions largely resolved by mid-November to December, with minimal residual impact on Q3 performance. * **Domestic Supply Focus:** Current model centered on "India for India" with only **limited cross-border supply during national emergencies** in the past year. ## C. NLEM Price Impact * **Volume Resilience:** Despite a **>55% price reduction**, Ceftum and T-Bact achieved significant value scale, demonstrating robust demand elasticity and market penetration. ## D. Value-Based Pricing * **Patient Value Perception:** Indian patients prioritize therapeutic value over cost alone; innovative products like **Shingrix** validate premium pricing when clinical benefit is clear. --- # 5. Commercial & Field Execution ## A. Key Figures * **Employees:** **3,000** enterprise-wide · **2,000** in sales force * HCP Touchpoints: 4 million total in quarter (face-to-face + digital) * **Oncology Team Size:** **~25** key account specialists * **Oncologist Coverage:** **1,000** covered in current universe ## B. Sales Force Productivity * **Stable, High-Productivity Model:** Sales force of 2,000 maintained over two years, supporting one of the highest rep productivities in the industry. * **Strategic Expansion into Specialties:** Field force growth now focused on specialty/super-specialty areas, with recent launch of oncology team and upcoming haematology rollout. * **Efficient Specialty Commercialization:** New product launches in oncology and hepatology require minimal field strength due to concentrated prescriber base and **targeted coverage model**. * **Seasonal Revenue Leverage:** PCPM shows expected seasonality, with uplift in Q3 driven by acute-care product demand. ## C. Omni-channel Engagement * **Digital Integration Driving Scale:** Near 4 crore HCP touchpoints achieved via blended face-to-face and digital engagement, reinforcing omnichannel as a value-creating commercial lever. ## D. HCP Coverage Model * **Specialty-Led Growth Trajectory:** Expansion prioritized in high-impact therapeutic areas like oncology and liver disease, where unmet need enables focused, high-efficiency market access. --- # 6. Regulatory & Pricing Risks ## A. Regulatory & Pricing Exposure * **Headline:** MIP inclusion of **Amoxiclav will not impact GSK’s margin, EBITDA, or gross margin**, signaling contained pricing risk for key antibiotic. * **Headline:** GenMed business is resilient to future NLEM revisions, with most brands in stable pricing bands and **no significant outliers**, limiting downside risk. * **Headline:** **One-third of portfolio under NLEM**, with **35% to 38% of total sales subject to price controls**, highlighting structural exposure to regulatory pricing. ## B. Approval Timelines & Market Access * **Headline:** Regulatory alignment with global launches remains aspirational; timing depends on Indian authorities’ review, though **Rule 101 enables concurrent approvals** if authorized in six reference countries. * **Headline:** Recent budget initiatives aim to **cut current 6–18 month approval lag**, with regulators signaling intent to accelerate processes—progress expected over coming quarters. ## C. Import Duty & Cost Implications * **Headline:** Duty-free import benefits for cancer drugs excluded GSK’s portfolio; company plans to **seek future inclusion via formal representations** to authorities. --- # 7. Guidance & Outlook ## A. Key Figures * Revenue Target: INR 7,000–8,000 Cr topline in 5–7 years (CAGR 12%–14%) * **Growth Guidance:** **12%–14% CAGR** targeted over next five years (FY23–24 base) ## B. Revenue Growth Target * **Conservative but Confident Trajectory:** Management maintains **12%–13% growth guidance** despite strong momentum, prioritizing sustainable performance over aggressive expansion. * **Near-Term Acceleration Expected:** With supply constraints resolved, **double-digit topline growth** is anticipated in upcoming quarters. * **Profit Growth in Line with Sales:** GSK expects **profitability to track revenue growth** over the next 3–5 years, supporting margin stability. ## C. Margin Sustainability * **Margin Hold Strategy:** Company intends to **sustain current EBITDA margins**, forgoing aggressive margin expansion to maintain competitiveness and fund growth investments. ## D. Long-term Portfolio Mix * **Shift to High-Growth Segments:** Portfolio is pivoting toward **Shingrix, Nucala Specialty, and oncology**, which offer higher margins and long-term share gain potential. * **Vaccines & Specialty to Drive Mix:** These higher-margin segments are expected to **increase their revenue share** over the next three years, underpinning profitability.